Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724416 | 0.95 | PDE10A (0.31) | — | |
| SCHEMBL4852619 | 0.80 | — | — | |
| SCHEMBL4852621 | 0.75 | — | — | |
| SCHEMBL22834968 | 0.74 | SLC6A2 (0.33) | — | |
| SCHEMBL467080 | 0.71 | SMN1; SMN2 (0.35) | GAASMN1; SMN2 | |
| SCHEMBL6189624 | 0.71 | HCAR3 (0.31) | — | |
| SCHEMBL2557814 | 0.69 | MEN1 (0.44) | NLRP3GAASMN1; SMN2 | |
| SCHEMBL10323402 | 0.69 | CFTR (0.38) | NLRP3GAASMN1; SMN2 | |
| SCHEMBL10323447 | 0.69 | CFTR (0.38) | NLRP3GAASMN1; SMN2 | |
| SCHEMBL10324942 | 0.69 | CFTR (0.38) | NLRP3GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | claimed |
| US-7897592-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-01 | — | — | US | claimed |
| US-7763630-B2 | pyrimidinone compounds such as N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-2-(tetrahydrofuran-3-yl)-1,6-dihydropyrimidine-4-carboxamide, used for treating human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | claimed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | claimed |
| WO-2008154246-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080306051-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-11 | — | — | US | claimed |
| EP-1749011-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-29 | — | — | EP | claimed |
| EP-1948666-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2007064619-A1 | PYRIMIDINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-07 | — | — | WO | claimed |
| US-20070129379-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-07 | — | — | US | claimed |
| WO-2007059125-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-24 | — | — | WO | claimed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | claimed |
| US-20070112190-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | claimed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | claimed |
| EP-1749011-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-07 | — | — | EP | claimed |
| US-7037908-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | claimed |
| WO-2005118593-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | claimed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-18 | — | — | US | claimed |
| WO-2004096128-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | DUT, CDK6, TYMS | NLRP3 587/4885HRH1 743/4885GAA 1910/4885 |
| US-20070129379-A1 | HIV INTEGRASE INHIBITORS | TYMP, POLN, IMPDH1 | NLRP3 1794/4885HRH1 2824/4885GAA 675/4885 |
| US-20080306051-A1 | HIV Integrase Inhibitors | TYMP, IMPDH1, UNG | NLRP3 2016/4885HRH1 3112/4885GAA 613/4885 |
| US-20070112190-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | NLRP3 1794/4885HRH1 2824/4885GAA 675/4885 |
| US-20070111984-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | NLRP3 1794/4885HRH1 2824/4885GAA 675/4885 |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | NLRP3 1418/4885HRH1 2081/4885GAA 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.